BeiGene (ONC) stock
Last close $399.70 on 2026-11-19 (-0.97%) · Sector: Healthcare
BeiGene is a biotechnology company that researches, develops, and sells medicines, mainly for cancer. It earns money by selling its approved treatments to hospitals and pharmacies and by partnering with other drug companies, and it reinvests a large share of that money into research.
BeiGene's sales are growing fast, with quarterly revenue up in each of the last several reported quarters and the latest quarter reaching about 1.9 billion dollars. The stock has returned 14.4 percent over the past year, beating the S&P 500's 9.7 percent, and it sits 5.9 percent below its 52-week high. Insiders have sold about 48.5 million dollars of stock over the last 90 days and have made no purchases. After earnings reports, the stock has more often risen the next day (4 times) than fallen (2 times), with moves usually under 6 percent.
Key numbers
- Market cap: $609.5B
- Revenue (last 12 months): $6.61B
- Revenue growth: +32.7%
- Gross margin: 89.5%
- Operating margin: 18.0%
- P/E: 655.2
- P/S: 92.2
- Debt to equity: 0.13
- Current ratio: 3.56
Quality score
Overall 45/100 · growth 56 · profitability 42 · financial health 83 · value 0
Performance and risk
1-year return +14.4% vs S&P 500 +9.7% · volatility 33.9% (S&P 500 13.8%) · largest drop -29.8% · beta 0.68
Stock move the day after earnings
- 2026-02-26: -8.5%
- 2026-04-14: +3.2%
- 2026-05-06: +5.3%
- 2026-08-05: +1.4%
- 2026-08-26: -0.2%
- 2026-11-05: +2.5%
Insider trades (12 months)
Bought $0.0M · sold $384.8M
ONC stock research · ONC options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.